January 2021

Ground-breaking research into the Hepatitis C virus made waves in virology this year after scientists successful identified the virus – earning them the Nobel Prize for Medicine. To find out how the researchers arrived at this development, we examine the challenge of identifying Hepatitis C, compared to A and B. Plus, following a nail-biting US election, we pick apart President-elect Joe Biden’s attitude toward the pharma industry and what the next four years could mean for companies operating in the US.

Also in this next issue, we track the rise of self-medication in pharma as the lines between healthcare types continues to blur, investigate the ethical implications of experimental achondroplasia treatments, and speak to industry insiders to understand what it takes to accelerate vaccine development.

Moreover, we review innovations in anti-counterfeit packaging formats for pharma products, ask if pharma’s net-zero goals will be enough to reverse the damage done by one of the world’s most carbon-heavy industries, and explore the clinical research potential of New Zealand.

EDITORIAL

Editor | Eloise McLennan

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Natalie Healey, Abi Millar, Chloe Kent, Chris Lo, Neli Ivanova
Magazine Designer | Marzia Del Gaone

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Filipe Costa, Martina Labaiova
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact: Susanne Hauner

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | The logistics of delivering a global vaccineGo to article: In this issueGo to article: ContentsGo to article: MimotopesGo to article: SHL MedicalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Solvias Company Insight Go to article: SolviasGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: SwiftpakGo to article: CommentGo to article: Long HCC pipeline marks change for a previously stagnant marketGo to article: Pfizer and BioNTech’s Covid-19 vaccine candidate shows 90% efficacyGo to article: Blockchain-enabled hospital can provide real-world dataGo to article: The increasing influence of industry sponsors along the pandemic timelineGo to article: Digitalisation in pharmaceutical manufacturingGo to article: VEGA AustraliaGo to article: KugelmeiersGo to article: Unither PharmaceuticalsGo to article: In DepthGo to article: Special delivery: the logistics of curing Covid-19 Go to article: Will there ever be an HIV vaccine?Go to article: Predicting Covid-19 vaccine approvals with OpylGo to article: Unequal access: understanding cancer treatment disparity in EuropeGo to article: ‘Trustpilot’ for medicines: can DrugsDiscovered help pharma be patient centric?Go to article: Q&A: investing in innovative biotechs with Novo VenturesGo to article: Gold standard: why are Phase III trials so critical?Go to article: Brewprint: using yeast to make plant-based drugsGo to article: Air FranceGo to article: Zenatek Company Insight Go to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue